5 Papers
13 Citations
Puja Garg is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Medicine & Balloon. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Endovascular treatment of infrainguinal chronic total occlusions using the TruePath device: features, handling, and 6-month outcomes.
Subhash Banerjee,Karan Sarode,Karan Sarode,Thomas Das,Omar Hadidi,Rahul Thomas,Rahul Thomas,Ariel Vinas,Ariel Vinas,Puja Garg,Atif Mohammad,Mirza S. Baig,Mirza S. Baig,Nicolas W. Shammas,Emmanouil S. Brilakis +14 more
TL;DR: TruePath facilitated successful crossing of infrainguinal CTOs following an unsuccessful guidewire recanalization, with significant improvement in symptoms and no complications.
21
Significance of an abnormal ankle-brachial index in patients with established coronary artery disease with and without associated diabetes mellitus.
Subhash Banerjee,Subhash Banerjee,Ariel Vinas,Ariel Vinas,Atif Mohammad,Omar Hadidi,Rahul Thomas,Karan Sarode,Karan Sarode,Avantika Banerjee,Puja Garg,Rick Weideman,Bertis B. Little,Emmanouil S. Brilakis,Emmanouil S. Brilakis +14 more
TL;DR: In patients with stable CAD, an abnormal ABI confers an incremental risk of MACE in addition to DM and traditional CV risk factors.
13
Blunt microdissection for endovascular treatment of infrainguinal chronic total occlusions.
Subhash Banerjee,Omar Hadidi,Atif Mohammad,Ali Y. Alsamarah,Rahul Thomas,Karan Sarode,Karan Sarode,Puja Garg,Mirza S. Baig,Mirza S. Baig,Emmanouil S. Brilakis +10 more
TL;DR: The CrossBoss blunt microdissection catheter facilitated successful crossing of CTOs in patients with infrainguinal lesions following unsuccessful guidewire crossing, with an acceptably low rate of periprocedural complications and significant improvement in symptoms.
11
Commentary: embolic capture angioplasty with the 300-mm-long proteus balloon.
TL;DR: Results indicate the safe and successful use of the long 53300-mm Proteus ECA balloon in a complex lesion and patient subset and, though these results are reassuring, inclusion of some important operational details might have further increased the practical significance of the report for practicing endovascular specialists.
Low-density lipoprotein cholesterol: how low can we go?
TL;DR: It is argued that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates and how to achieve very low levels of plasma cholesterol using both traditional and novel LDL-lowering therapies is discussed.